iBio, Inc. Files 8-K: Material Agreement, Exhibits

Ticker: IBIO · Form: 8-K · Filed: 2025-04-22T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, filing, exhibits

TL;DR

iBio filed an 8-K on 4/21/25 for a material agreement. Details to follow.

AI Summary

On April 21, 2025, iBio, Inc. entered into a Material Definitive Agreement. The filing also includes a Regulation FD Disclosure and Financial Statements and Exhibits. The company is incorporated in Delaware and its principal executive offices are located in Bryan, Texas.

Why It Matters

This 8-K filing indicates a significant event for iBio, Inc., likely related to a new contract or partnership, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Material Definitive Agreements can introduce new risks or opportunities, and the lack of specific details in this initial filing warrants a medium risk assessment.

Key Players & Entities

FAQ

What is the nature of the Material Definitive Agreement entered into by iBio, Inc. on April 21, 2025?

The filing does not specify the nature of the Material Definitive Agreement, only that one was entered into on April 21, 2025.

What are the principal executive offices of iBio, Inc.?

The principal executive offices of iBio, Inc. are located at 8800 HSC Parkway, Bryan, Texas 77807.

When was iBio, Inc. incorporated?

iBio, Inc. was incorporated in Delaware.

What is the Commission File Number for iBio, Inc.?

The Commission File Number for iBio, Inc. is 001-35023.

What other items are included in this 8-K filing besides the Material Definitive Agreement?

This 8-K filing also includes a Regulation FD Disclosure and Financial Statements and Exhibits.

From the Filing

0001420720-25-000020.txt : 20250422 0001420720-25-000020.hdr.sgml : 20250422 20250422164130 ACCESSION NUMBER: 0001420720-25-000020 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20250421 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250422 DATE AS OF CHANGE: 20250422 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 25858228 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 8-K 1 ibio-20250421x8k.htm 8-K iBio, Inc._April 21, 2025 0001420720 false 0001420720 2025-04-21 2025-04-21 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 21, 2025 iBio, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) ​ ​ 001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.) ​ 8800 HSC Parkway Bryan , Texas 77807 (Address of principal executive offices and zip code) ( 979 ) 446-0027 (Registrant’s telephone number including area code) N/A (Former Name and Former Address) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions: ☐       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐       Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) ☐       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock , $0.001 par value per share IBIO The Nasdaq Stock Market LLC ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ ​ ​ ​ ​ Item 1.01. Entry Into a Material Definitive Agreement. ​ Exclusive License Agreement ​ On April 21, 2025, iBio, Inc. (the “Company”), entered into an exclusive agreement (the “License Agreement”) with AstralBio, Inc. (“AstralBio”), pursuant to which AstralBio has licensed to the Company, on an worldwide exclusive basis and with the right to grant sublicenses, under the AstralBio Licensed Patents a

View on Read The Filing